Condition
Recurrent Squamous Cell Lung Carcinoma
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 12 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
12 shownLung-MAP S1400K: c-MET PositiveNCT03574753 · 2018-03-16
COMPLETEDDurvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung CancerNCT03373760 · 2017-11-30
COMPLETEDLung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung CancerNCT03377556 · 2017-03-03
COMPLETEDLung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersNCT02785952 · 2015-12-29
ACTIVE_NOT_RECRUITINGSelinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung CancerNCT02536495 · 2015-09-01
WITHDRAWNLung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesNCT02785913 · 2014-11-01
COMPLETEDLung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02965378 · 2014-10-01
COMPLETEDLung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02785939 · 2014-09-01
COMPLETEDLung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersNCT02766335 · 2014-07-31
COMPLETEDLung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02154490 · 2014-07-08
COMPLETEDLung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesNCT02926638 · 2014-06-16
TERMINATEDS0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung CancerNCT00946712 · 2009-07-15
TERMINATEDCommon interventions
Laboratory Biomarker AnalysisOTHER11DocetaxelDRUG5DurvalumabBIOLOGICAL3Pharmacological StudyOTHER3Erlotinib HydrochlorideDRUG2FGFR Inhibitor AZD4547DRUG2IpilimumabBIOLOGICAL2NivolumabBIOLOGICAL2PalbociclibDRUG2RilotumumabBIOLOGICAL2TalazoparibDRUG2TaselisibDRUG2TremelimumabBIOLOGICAL2ABBV-399DRUG1BevacizumabBIOLOGICAL1CarboplatinDRUG1CetuximabBIOLOGICAL1PaclitaxelDRUG1Quality-of-Life AssessmentOTHER1Questionnaire AdministrationOTHER1SelinexorDRUG1
Leading sponsors
Trial status mix
COMPLETED8
TERMINATED2
ACTIVE_NOT_RECRUITING1
WITHDRAWN1
Phase mix
PHASE29
PHASE36
PHASE11
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.